KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Difelikefalin in Chinese patients with chronic kidney disease-associated pruritus.

Li Zuo, Liangying Gan, Tianjun Guan, Weiming He, Hong Ye, Qingfeng Peng, Bin Liu, Houyong Dai, Yinggui Ba, Lanfen Xue, Murray Lowe, Milica Enoiu

Clin Kidney J 19(4) sfag031

PMID41948117
PMCIDPMC13053084
DOI10.1093/ckj/sfag031
发表日期2026-04-08
摘要

摘要

BACKGROUND: Chronic kidney disease-associated pruritus (CKD-aP) is a common and debilitating condition in patients receiving in-centre haemodialysis. This study evaluated the efficacy and safety of difelikefalin (a new, intravenous treatment for moderate-to-severe CKD-aP approved in >40 countries) in a Chinese population receiving haemodialysis. METHODS: This Phase 3, multicentre, randomized placebo-controlled study included a 12-week double-blind treatment period, during which patients received either difelikefalin or placebo, followed by an optional 14-week open-label extension, in which all patients received difelikefalin. Endpoints included change from baseline in the Worst Itching Intensity Numerical Rating Scale (WI-NRS) at Week 4 (primary endpoint), the percentage of patients achieving a clinically relevant ≥3-point change in WI-NRS, patient-reported health-related quality-of-life measures, and incidence of adverse events. RESULTS: Difelikefalin-treated patients showed significantly greater improvements in least squares mean change from baseline in WI-NRS at Week 4 of the double-blind period compared with placebo [difelikefalin minus placebo: -0.81 (95% confidence interval: -1.25, -0.37); P = .0003], and patients with ≥3-point improvement in WI-NRS at Week 12 (48.7% versus 33.8%, nominal P = .0235). Difelikefalin also improved health-related quality of life, with clinically relevant changes observed in 5-D itch and Skindex-10 in most patients at Week 4 of the open-label extension (estimated ≥62% and ≥56%, respectively). Adverse events were mostly mild or moderate in severity and generally consistent with the known safety profile of difelikefalin. CONCLUSION: Difelikefalin effectively reduced pruritus intensity and improved quality of life in Chinese patients with CKD-aP receiving haemodialysis, supporting its use in this population.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。